Molecular characterization and prognostic significance of FLT3 in CML progression
Kyung Im Kim(Korea University), Jung Mi Oh(Seoul National University), Sung‐Soo Yoon(Seoul National University Hospital), Kwang-Sung Ahn(Sungkyunkwan University), Byoung Kook Kim(Seoul National University), Juwon Park(Seoul National University), N H Won(Korea University), Wan Gyoon Shin(Seoul National University)
Cited by 10
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
|Blood|2014|140